# Diranersen (BIIB080)

Source: https://onco.cc/drugs/da-biib080/  
OnCo record `da-biib080` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

BIIB080 is an investigational tau-lowering antisense medicine. It is not an approved dementia treatment.

## Summary

Biogen’s intrathecal ASO programme targets tau RNA. Phase 2 safety and cognition outcomes are still being established. Not for self-administration.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-21
- Tags: dementia-atlas
- Code: BIIB080
- Modality: ASO
- Mechanism: Investigational antisense oligonucleotide aimed at reducing MAPT / tau expression.

## Sources

- ClinicalTrials.gov NCT05399888: https://clinicaltrials.gov/study/NCT05399888

## Connected records

- diagnoses: [Alzheimer’s disease](https://onco.cc/diagnoses/alzheimers-disease/), [Mild cognitive impairment](https://onco.cc/diagnoses/mild-cognitive-impairment/)
- targets: [Tau](https://onco.cc/targets/da-target-tau/)
- companies: [Biogen](https://onco.cc/companies/da-biogen/)
- trials: [Diranersen / BIIB080 Phase 2](https://onco.cc/trials/da-trial-biib080/)
- technologies: [Tau-directed therapeutics](https://onco.cc/technologies/da-tech-tau-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/da-biib080.json